Samuel D. Isaly, Director at Adaptimmune Therapeutics PLC (ADAP), bought 2,380,952 shares at $4.20 ($10.0M) on 2017-03-27, disclosed to the SEC on 2017-03-28.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.20 | 1,190,476 | $5.0M | 50.0% |
| 2 | $4.20 | 1,190,476 | $5.0M | 50.0% |
| Total | $4.20 avg | 2,380,952 | $10.0M | 100% |
| Filing → |
| RYTM | BUY | 2017-10-10 | $6.0M | — | Filing → |
| BOLD | SELL | 2017-09-29 | $19.0M | — | Filing → |
| ROKA | SELL | 2017-09-28 | $202K | — | Filing → |